Literature DB >> 2545454

Enalapril and hydrochlorothiazide in hypertensive Africans.

A A Ajayi1, E A Oyewo, G O Ladipo, A Akinsola.   

Abstract

The antihypertensive efficacy both of angiotensin converting enzyme (ACE) inhibitors and thiazide diuretics has been claimed to be influenced by plasma renin activity, which declines with age and is low in blacks. In a double-blind, placebo-controlled, double-dummy, randomized, parallel-group preliminary study, the antihypertensive efficacy and tolerability of the ACE inhibitor enalapril (20 mg day-1) and hydrochlorothiazide (50 mg day-1) were evaluated and compared for 4 weeks in 20 African patients with essential hypertension. The two groups had similar baseline clinical features and serum Na+ and K+ levels. Hydrochlorothiazide caused a significant and sustained fall in erect blood pressure with a reflex tachycardia. Enalapril exerted only a modest antihypertensive action, but significantly reduced erect heart rate. Direct comparison of hydrochlorothiazide- and enalapril-induced hypotension suggested a greater fall in subjects on the thiazide. The 95% confidence limits for the thiazide-enalapril difference in antihypertensive action at the end of the study was 39.5 to -7.5 mm Hg systolic and 22.0 to -6.6 mm Hg diastolic. The maximal blood pressure fall after hydrochlorothiazide was positively correlated with age (r = 0.50; p less than 0.05), whilst that of enalapril was inversely related age to (r = -0.57, p less than 0.05). The results are compatible with the notion that ACE inhibitor monotherapy may be less effective than thiazide diuretic treatment in African and black patients with essential hypertension. The findings also support the concept that age and racial factors may influence the response to antihypertensive treatment.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545454     DOI: 10.1007/BF00558152

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

1.  Antihypertensive beta blocking action as related to renin and age: a pharmacologic tool to identify pathogenetic mechanisms in essential hypertension.

Authors:  F R Bühler; F Burkart; B E Lütold; M Küng; G Marbet; M Pfisterer
Journal:  Am J Cardiol       Date:  1975-10-31       Impact factor: 2.778

2.  Monotherapy with nifedipine for essential hypertension in adult blacks.

Authors:  M O Fadayomi; K K Akinroye; R O Ajao; L A Awosika
Journal:  J Cardiovasc Pharmacol       Date:  1986 May-Jun       Impact factor: 3.105

3.  Vasoconstriction-volume analysis for understanding and treating hypertension: the use of renin and aldosterone profiles.

Authors:  J H Laragh
Journal:  Am J Med       Date:  1973-09       Impact factor: 4.965

4.  Propranolol in the South African non-white hypertensive patient.

Authors:  Y K Seedat; J Reddy
Journal:  S Afr Med J       Date:  1971-03-13

5.  Evolution of diuretics and ACE inhibitors, their renal and antihypertensive actions--parallels and contrasts.

Authors:  A F Lant
Journal:  Br J Clin Pharmacol       Date:  1987       Impact factor: 4.335

6.  Acute and chronic effects of the converting enzyme inhibitors enalapril and lisinopril on reflex control of heart rate in normotensive man.

Authors:  A A Ajayi; B C Campbell; C A Howie; J L Reid
Journal:  J Hypertens       Date:  1985-02       Impact factor: 4.844

7.  Plasma renin activity and plasma aldosterone concentrations in untreated Nigerians with essential hypertension.

Authors:  B Osotimehin; R T Erasmus; A O Iyun; A O Falase; Z Ahmad
Journal:  Afr J Med Med Sci       Date:  1984 Sep-Dec

8.  Blood pressure, plasma volume, and catecholamine levels during enalapril therapy in blacks with hypertension.

Authors:  P A Freier; G L Wollam; W D Hall; D J Unger; M B Douglas; R P Bain
Journal:  Clin Pharmacol Ther       Date:  1984-12       Impact factor: 6.875

9.  The epidemiology of plasma renin.

Authors:  T W Meade; J D Imeson; D Gordon; W S Peart
Journal:  Clin Sci (Lond)       Date:  1983-03       Impact factor: 6.124

10.  A controlled multiclinic study to compare the antihypertensive effects of MK-421, hydrochlorothiazide, and MK-421 combined with hydrochlorothiazide in patients with mild to moderate essential hypertension.

Authors:  D G Vidt
Journal:  J Hypertens Suppl       Date:  1984-12
View more
  8 in total

1.  Angioedema and cough in Nigerian patients receiving ACE inhibitors.

Authors:  A A Ajayi; A Q Adigun
Journal:  Br J Clin Pharmacol       Date:  2000-07       Impact factor: 4.335

2.  Angiotensin converting enzyme inhibition reduces proteinuria in Nigerians with chronic renal disease.

Authors:  A A Ajayi; A T Ajayi
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

3.  Increased C-reactive protein in ACE-inhibitor-induced angioedema.

Authors:  M Bas; T K Hoffmann; H Bier; G Kojda
Journal:  Br J Clin Pharmacol       Date:  2005-02       Impact factor: 4.335

Review 4.  Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

5.  The efficacy and tolerability of amlodipine and hydrochlorothiazide in Nigerians with essential hypertension.

Authors:  A A Ajayi; A O Akintomide
Journal:  J Natl Med Assoc       Date:  1995-07       Impact factor: 1.798

Review 6.  Pathophysiologically based antihypertensive pharmacotherapeutics rationality, efficacy and safety in Sub Saharan African Nations - A review.

Authors:  A A L Ajayi; O E Ajayi
Journal:  Int J Cardiol Cardiovasc Risk Prev       Date:  2021-10-28

7.  A comparative evaluation of fixed dose and separately administered combinations of lisinopril and hydrochlorothiazide in treatment-naïve adult hypertensive patients in a rural Nigerian community.

Authors:  Ugochinyere Ogudu; Obiyo Nwaiwu; Olumuyiwa John Fasipe
Journal:  Int J Cardiol Cardiovasc Risk Prev       Date:  2022-08-05

8.  Pharmacotherapy for hypertension in Sub-Saharan Africa: a systematic review and network meta-analysis.

Authors:  Anna Seeley; Josephine Prynn; Rachel Perera; Rebecca Street; Daniel Davis; Anthony O Etyang
Journal:  BMC Med       Date:  2020-03-27       Impact factor: 8.775

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.